Glioblastoma Multiforme (GBM) – Cell and Gene Therapies 15-Market Assessment and Sales Forecast to 2031
Powered by ![]()
All the vital news, analysis, and commentary curated by our industry experts.
Glioblastoma Multiforme (GBM) – Cell and Gene Therapies 15-Market Report Overview
The total market value for the 15M, which includes both CGTs and established/traditional GBM therapies was $630 million in 2021. High usage of dendritic cell vaccines and oncolytic viruses that demonstrate significant survival advantages will drive market growth during the forecast period.
Glioblastoma Multiforme (GBM) – Cell and Gene Therapies 15-Market Outlook, 2021-2031 ($ Billion)
Buy the Full Report to Know More about the Glioblastoma Multiforme (GBM) – Cell and Gene Therapies 15-Market Forecast
The GBM – -cell and gene therapies 15-market research report offers a comprehensive insight into the market through 2032. The report provides an overview of the disease including epidemiology, symptoms, diagnosis, disease management, countries where the disease is prevalent, and leading players associated with the market.
| Market Size (2021) | $630 billion |
| Forecast Period | 2021-2031 |
| Key Regions | · APAC
· Europe · Middle East · North America |
| Leading Players | · Istari Oncology Inc
· Immunomic Therapeutics Inc · Vascular Biogenics Ltd · Istari Oncology Inc · UWELL Biopharma Inc |
| Enquire & Decide |
Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
Glioblastoma Multiforme (GBM) – Cell and Gene Therapies 15-Market Dynamics
Not all patients are eligible to receive CGT agents as many clinical trials exclude patients with KPS >60. Additionally, they have stringent entry criteria which is hampering the market growth. However, one of the highest levels of unmet need across all of oncology is expected to significantly drive the uptake and usage of novel CGT agents in the coming years.
Glioblastoma Multiforme (GBM) – Cell and Gene Therapies 15-Market Analysis by Treatment
- Effective and relatively safe treatment for brain edema and reduces patient steroid burden.
- Gliadel is used in addition to other therapies so patients can still follow the regular treatment paradigm following Gliadel implantation.
Buy Full Report for More Insights into the Glioblastoma Multiforme (GBM) – Cell and Gene Therapies 15-Market Treatment
Glioblastoma Multiforme (GBM) – Cell and Gene Therapies 15-Market Segmentation by Regions
North America had the highest sales in 15MM in the GBM-cell and gene therapies 15-market.
A few of the key regions in the market are APAC, Europe, Middle East, and North America.
Glioblastoma Multiforme (GBM) – Cell and Gene Therapies 15-Market Analysis by Regions, 2021 (%)
Buy Full Report for More Regional Insights into the Glioblastoma Multiforme (GBM) – Cell and Gene Therapies 15-Market
Glioblastoma Multiforme (GBM) – Cell and Gene Therapies 15-Market -Competitive Landscape
Most CGT future players in GBM are US- and China-based biotech companies with a clear absence of big pharma developing CGT agents for GBM. The current major player in GBM is Roche, owing to the usage of its VEGF inhibitor Avastin (bevacizumab). However, Avastin is set to experience competition from Bayer’s regorafenib, which targets the same VEGF pathway.
A few of the major players in the Glioblastoma Multiforme (GBM) – Cell and Gene Therapies 15-market are:
- Istari Oncology Inc
- Immunomic Therapeutics Inc
- Vascular Biogenics Ltd
- Istari Oncology Inc
- UWELL Biopharma Inc
Glioblastoma Multiforme (GBM) – Cell and Gene Therapies 15-Market Analysis by Companies
Buy the Full Report to Know More about Companies in the Glioblastoma Multiforme (GBM) – Cell and Gene Therapies 15-Market
Glioblastoma Multiforme (GBM) – Cell and Gene Therapies 15-Country Outlook (Value, $ Billion, 2021-2031)
- APAC
- Europe
- Middle East
- North America
Scope
- Overview of Glioblastoma Multiforme including epidemiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
- Topline Glioblastoma Multiforme market revenue, annual cost of therapy, and major pipeline product sales in the forecast period.
- Key topics covered include current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting Glioblastoma Multiforme therapeutics sales in the 8MM.
- Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs (Phase II-III).
- Analysis of the current and future market competition in the global Glioblastoma Multiforme therapeutics market. Insightful review of the key industry drivers and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
Key Highlights
- Report deliverables include a PowerPoint report and an Excel-based forecast model.
- Forecast includes 8 countries.
- Forecast covers 2021-2031.
- Seven markets are extrapolated, obtaining a 15-market value for all GBM therapeutics.
Reasons to Buy
- Obtain cell & gene therapy sales forecasts across multiple regions
- Gain insight into promising early-stage approaches
Our indication-specific forecast models answer questions such as:
- What is the target patient pool for cell & gene therapies in each cancer indication?
- Which patient groups are more likely to receive these therapies?
- What does the cell & gene therapy clinical-stage pipeline look like in each cancer indication
- What is the anticipated breakdown between autologous and allogeneic cell therapies?
- When will cell & gene therapies launch in each market?
- What is the total market value projected for the forecast end, in 2031?
Epitopoietic Research Corporation
Istari Oncology
Table of Contents
Frequently asked questions
-
What was the GBM – Cell and Gene Therapies 15-market size across the 8MM in 2021?
The total market value for the 15M, which includes both CGTs and established/traditional GBM therapies was $630 million in 2021.
-
Which region had the highest sales in the GBM– Cell and Gene Therapies 15-market?
North America held the highest sales in the GBM– Cell and Gene Therapies 15-market across the 8MM in 2021.
-
Who are the leading players operating in the GBM– Cell and Gene Therapies 15 market?
A few of the major players in the GBM–cell and gene therapies 15-market are Istari Oncology Inc., Immunomic Therapeutics Inc., Vascular Biogenics Ltd, Istari Oncology Inc., and UWELL Biopharma Inc. among others.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Glioblastoma Multiforme (GBM) reports

